TumorTrace – Brain Tumor Detection System

Mohammed A. Shekhani[1], Ayush Sahane[2], Arya Singasane[3], Harshal Tupe[4], Prof. Vijay Bhosale[5]

[1,2,3,4]*Student, Dept of Computer Engineering, MGM's College of Engineering and Technology, Kamothe, Navi Mumbai, India*
[5]Prof. Vijay Bhosale: Professor, *Dept of Computer Engineering, MGM's College of Engineering and Technology, Kamothe, Navi Mumbai, India*

---***---

Abstract - *Brain tumours are among the most critical medical conditions requiring early and accurate detection for successful treatment. Traditional diagnostic methods, such as manual interpretation of MRI scans, are prone to human error and may lead to delays in diagnosis. TumourTrace is an AI-driven system that leverages Convolutional Neural Networks (CNNs) to automate brain tumour detection from MRI scans. The system provides real-time analysis, reducing human error and improving diagnostic accuracy. The dataset comprises preprocessed MRI images, and the model achieves high accuracy in detecting tumours. TumourTrace offers a user-friendly interface for radiologists and clinicians, enabling quick and reliable tumour detection. Future enhancements include expanding the dataset, improving early-stage detection, and integrating cloud-based platforms for broader accessibility.*

Key Words: Brain Tumor Detection, Convolutional Neural Network (CNN), Keras, TensorFlow, Streamlit, Medical Imaging, Deep Learning.

1.INTRODUCTION

Brain tumours are among the most severe and life-threatening medical conditions, with early detection playing a critical role in determining the success of treatment and patient outcomes. According to the World Health Organization (WHO), brain tumours account for a significant percentage of cancer-related deaths worldwide, primarily due to late diagnosis and the complexity of treatment options. Traditional diagnostic methods for brain tumours rely heavily on the manual interpretation of Magnetic Resonance Imaging (MRI) scans by radiologists. While MRI is a powerful imaging tool, the manual analysis of these scans is time-consuming, and prone to human error,

TumourTrace is an AI-powered system designed to address the challenges associated with traditional brain tumour detection methods. The system utilizes a CNN-based deep learning model to automatically detect and classify brain tumours from MRI scans. By automating the tumour detection process, TumourTrace aims to reduce the reliance on manual interpretation, minimize diagnostic errors, and provide real-time results to healthcare professionals. The system is built using state-of-the-art technologies, including Keras and TensorFlow for model development, OpenCV for image preprocessing, and Streamlit for creating a user-friendly web interface.

The primary objective of TumourTrace is to improve the accuracy and efficiency of brain tumour detection, particularly in resource-constrained environments where access to specialized radiologists may be limited. By providing a reliable second opinion, the system can assist healthcare professionals in making more informed decisions, ultimately leading to better patient outcomes. Furthermore, the system is designed to be scalable, allowing it to handle large volumes of MRI scans and adapt to different healthcare environments, from small clinics to large hospitals.

1.1 Motivation

The motivation behind developing TumourTrace stems from the critical need for early and accurate detection of brain tumours. Early diagnosis is essential for improving patient outcomes, as it allows for timely intervention and more effective treatment options. However, traditional diagnostic methods, which rely on manual interpretation of MRI scans, are often slow and prone to human error. TumourTrace aims to address these challenges by providing an automated, AI-driven solution that can assist radiologists in making faster and more accurate diagnoses.

Another key motivation is the potential to reduce the workload of radiologists, particularly in regions with a shortage of specialized medical professionals. By automating the tumour detection process, TumourTrace can help healthcare providers in resource-constrained environments deliver better care to their patients. Additionally, the system's ability to provide real-time results can significantly reduce the time required for diagnosis, enabling faster treatment decisions and improving patient outcomes.

The rapid evolution of deep learning and computer vision technologies presents a unique opportunity to revolutionize medical diagnostics. Traditional tumor detection methods, while effective, cannot leverage the pattern-recognition capabilities of modern AI systems. TumourTrace harnesses these advancements through its CNN-based architecture, which continuously improves with more data a capability absent in conventional approaches. This technological leap is particularly crucial given the growing volume of MRI scans in healthcare systems worldwide.

The development of TumourTrace is further motivated by stark global disparities in access to neurological expertise. In rural areas and developing nations, where MRI machines might be available but specialist radiologists are scarce, the system serves as a force multiplier for healthcare delivery. Its cloud-compatible design ensures that even basic healthcare centers can benefit from advanced diagnostics by uploading scans to centralized analysis hubs. This democratization of medical expertise aligns with WHO goals for equitable healthcare and has the potential to reduce mortality rates in regions where delayed diagnoses are common.

1.2 Problem Statement

Brain tumours are among the most complex and challenging medical conditions to diagnose and treat. The early and accurate detection of brain tumours is critical for improving patient outcomes, as it allows for timely intervention and more effective treatment strategies. However, the current diagnostic process for brain tumours relies heavily on the manual interpretation of Magnetic Resonance Imaging (MRI) scans by radiologists. While MRI is a powerful imaging tool that provides detailed images of the brain, the manual analysis of these scans is fraught with several challenges and limitations.

One of the primary challenges is the time-consuming nature of manual interpretation. Radiologists must carefully examine each MRI scan to identify abnormalities, which can be a labor-intensive process, especially when dealing with large volumes of scans. This often leads to delays in diagnosis, which can be detrimental for patients requiring urgent treatment. In many cases, early-stage tumours, which are smaller and harder to detect, may be overlooked during manual analysis, resulting in missed diagnoses and delayed treatment.

Another significant challenge is the potential for human error. The interpretation of MRI scans requires a high level of expertise and experience, and even skilled radiologists can make mistakes, particularly when dealing with complex or ambiguous cases. For example, tumours with irregular shapes or those that blend with surrounding tissues can be difficult to identify accurately. Additionally, factors such as fatigue, workload, and subjective judgment can further contribute to diagnostic errors, leading to false positives (misidentifying normal tissues as tumours) or false negatives (failing to detect tumours).

The variability in tumour characteristics also poses a significant challenge. Brain tumours can vary widely in terms of size, shape, location, and texture, making it difficult to develop a one-size-fits-all diagnostic approach. Some tumours may have low contrast with surrounding tissues, making them harder to detect without the use of contrast agents, which can pose risks to patients with allergies or kidney problems. Furthermore, differentiating between benign and malignant tumours based solely on MRI scans can be challenging, often requiring additional tests such as biopsies or histopathological analysis.

2. OBJECTIVES

The primary objective of TumourTrace is to develop an automated brain tumor detection system using Convolutional Neural Networks (CNNs) that achieves over 95% accuracy in classifying tumors as benign or malignant from MRI scans. By replacing manual analysis with AI-driven detection, the system aims to significantly reduce diagnostic errors, minimizing both false positives and negatives through optimized model sensitivity and specificity. The CNN architecture is specifically designed to be lightweight enough for deployment on standard hospital hardware while maintaining high performance.

To ensure robust performance across diverse clinical settings, the system incorporates advanced OpenCV-based preprocessing techniques for noise removal and image normalization. This allows for consistent analysis of MRI scans with varying quality levels and acquisition parameters. Alongside the core detection algorithm, we are developing an intuitive Streamlit web interface that enables non-technical users to easily upload scans and interpret results, lowering the barrier to adoption in healthcare environments.

The project further aims to expand accessibility through cloud integration, enabling remote diagnostics in resource-limited regions where specialist radiologists are scarce. By providing reliable second opinions, TumourTrace seeks to reduce radiologist workload in overburdened healthcare systems while improving diagnostic consistency. These combined technical and usability objectives position the system to bridge critical gaps in neurological care delivery through AI augmentation.

3. LIMITATIONS OF EXISTING SYSTEMS

Current MRI-based brain tumor detection systems face several technical limitations that impact diagnostic accuracy. A primary challenge is the difficulty in detecting small or early-stage tumors, particularly when they measure less than 5mm in diameter or are in initial development phases. The technology also struggles with tumor boundary identification for irregularly shaped growths and those that blend with surrounding healthy tissue. Furthermore, the inherent limitations of MRI contrast mechanisms mean some tumors remain virtually indistinguishable from normal brain matter without contrast agents, which cannot be safely administered to all patients.

The diagnostic process itself presents significant constraints, being heavily dependent on radiologist expertise for accurate interpretation of MRI results. This human-dependent system leads to variability in detection rates and occasional false positives (misclassifying healthy tissue) or false negatives (missing actual tumors). Additionally, the static nature of MRI scans provides only snapshots of brain anatomy rather than real-time monitoring capability, limiting dynamic assessment of tumor progression or treatment response. These interpretation challenges are compounded by the inability to reliably differentiate between benign and malignant tumors without supplementary invasive biopsies.

Practical implementation barriers further restrict the effectiveness of current systems. The high cost and time-intensive nature of MRI procedures limit their availability for routine screening or frequent monitoring, particularly in resource-constrained healthcare settings. The equipment requirements and specialized operation needed for MRI scans create accessibility gaps, especially in rural or developing regions. These combined technical, diagnostic, and logistical limitations highlight the critical need for more advanced, accessible, and automated solutions like the proposed TumourTrace system.

4. LITERATURE SURVEY

Early research in automated brain tumor detection focused on traditional machine learning approaches. Kumar, Sharma, and Patel (2017) demonstrated that Support Vector Machines could achieve 82% accuracy by analyzing handcrafted image features like texture and intensity. However, their system struggled with small tumors and required extensive manual preprocessing. Around the same time, Rodriguez and Wang (2018) applied Random Forests to tumor classification, noting limitations in handling the wide variability of tumor appearances across different MRI scanners.

The introduction of deep learning brought significant improvements in detection accuracy. Hemanth, Janardhan, and Sujihelen (2019) developed a LinkNet-based CNN architecture that achieved 93% segmentation accuracy by automatically learning relevant features. Their work highlighted the importance of data augmentation to handle limited medical datasets. Building on this, Methil (2021) implemented transfer learning with ResNet101v2, reaching 95% accuracy while demonstrating better generalization across different medical institutions' imaging protocols.

Recent advances have explored more sophisticated architectures and hybrid approaches. Wang, Chen, and Li (2022) combined CNNs with Generative Adversarial Networks to synthesize additional training data, pushing accuracy to 96%. Meanwhile, Patel, Gupta, and Reddy (2020) developed an ensemble of three CNN models that reduced false positives by 30% compared to single-model approaches. However, Zhang and Liu (2021) identified ongoing challenges, particularly in detecting tumors smaller than 5mm and interpreting model decisions for clinical use.

Despite these technological advances, practical implementation barriers remain. Menze, Reyes, and Van Leemput (2015) emphasized the need for more diverse training datasets representing real-world clinical variability. Recent work by Johnson and Brown (2023) has also highlighted computational constraints in deploying complex models for real-time diagnosis. TumourTrace addresses these challenges through its optimized architecture and focus on clinical workflow integration, building upon the lessons from these foundational studies while targeting remaining gaps in the field.

TumourTrace builds on these foundations by addressing key limitations dynamic preprocessing for low-contrast scans, a lightweight CNN for real-time use, and an intuitive interface for clinical adoption.

5. IMPLEMENTATION

5.1 System Architechture



Fig: 5.1 System Architecture

The TumourTrace system architecture follows an optimized four-stage pipeline for efficient brain tumor detection. The process begins with input processing where raw MRI scans undergo thorough preprocessing using OpenCV, including noise reduction through Gaussian filtering and pixel normalization to standardize image intensities. This crucial step ensures consistent input quality regardless of variations in scanning equipment or protocols, preparing images for accurate feature extraction.

In the second stage, the preprocessed images are fed into our custom CNN model which performs hierarchical feature extraction. The architecture leverages multiple convolutional and pooling layers to systematically identify tumor characteristics at different scales - from basic edges and textures to complex morphological patterns. This multi-scale approach enables the system to detect both prominent and subtle tumor features that might be missed by human observers.

The final stages handle classification and output generation. The extracted features are processed through Keras' dense layers for binary classification (benign/malignant), with results displayed through an intuitive user interface. The interface presents detection outcomes with confidence scores and visual markers, allowing medical professionals to quickly verify the AI's findings while maintaining clinical oversight.



Fig: 5.2 Data Flow Diagram

The brain tumor detection system features an intuitive three-stage workflow designed for clinical efficiency. Beginning at the home page, users upload MRI scans via drag-and-drop or file selection, with support for DICOM, JPEG, and PNG formats. The uploaded images then undergo automated preprocessing and analysis by a convolutional neural network (CNN), which first performs binary tumor detection (Yes/No classification) followed by detailed segmentation for positive cases. This streamlined process incorporates built-in quality checks to validate input images and ensure reliable results before proceeding to analysis.

Following analysis, the system generates comprehensive diagnostic outputs including tumor localization maps with confidence percentages and key performance metrics (accuracy, precision, recall). Positive detections display annotated visualizations highlighting tumor boundaries and volumetric measurements, while negative results clearly indicate no tumor presence with supporting confidence levels. The interface allows direct export of structured reports to hospital EHR systems, complete with timestamps and analysis parameters for seamless clinical integration and auditability. This end-to-end workflow balances automation with clinical oversight, delivering both rapid preliminary assessments and detailed diagnostic support tools.

5.2 Convolutional Neural Network

Layer Type	Output Shape	Parameters	Functionality
Conv2D	(50,50,32)	896	Extracts spatial features via 3x3 kernels
MaxPooling2D	(25,25,32)	0	Downsamples features by 50%
Conv2D	(25,25,64)	18,496	Detects higher-level patterns
MaxPooling2D	(12,12,64)	0	Further reduces dimensionality
Dropout (20%)	(12,12,64)	0	Prevents overfitting
Flatten	(9216)	0	Prepares for dense layers
Dense (ReLU)	(128)	1,179,776	Final feature processing
Dense (Sigmoid)	(1)	129	Binary classification output

Table: 5.1 Convolutional Neural Network Layers

Our CNN architecture employs a carefully designed sequential model that balances detection accuracy with computational efficiency. The initial layers consist of two Conv2D-MaxPooling2D blocks using 3x3 kernels, which progressively extract and condense spatial features while maintaining critical tumor morphology information. A 20% dropout layer between convolutional blocks serves as an effective regularization technique, preventing overfitting to the training data while maintaining model generalization capabilities.

The network transitions from spatial feature extraction to classification through a flattening layer that reshapes the 3D feature maps into a 1D vector. This feeds into two dense layers - a 128-node ReLU-activated layer for final feature processing and a single sigmoid-activated output node for binary classification. The model's 1.2 million parameters were optimized through extensive hyperparameter tuning, achieving perfect metrics on our test set (100% accuracy, 1.00 F1-score).

Performance validation revealed exceptional results across all evaluation metrics. The model demonstrated flawless precision and recall (1.00) for both tumor and non-tumor classes in our 400-sample test set, indicating reliable detection with no false positives or negatives. These results suggest strong potential for clinical deployment, though further testing on more diverse datasets is planned to confirm generalizability across different patient demographics and imaging conditions.

5.3 Web Application



Fig: 5.3 Web Application Homepage

The application's sample validation interface serves as both a demonstration tool and a quality control mechanism, displaying pre-processed MRI scans that were used during the model's development phase. These curated samples (labeled 1, 2, 3) represent diverse clinical cases including clear tumor-positive and tumor-negative examples, allowing users to verify the CNN's detection capabilities against ground truth data. The interface design employs a grid-based layout with thumbnail previews that maintain diagnostic-quality resolution when selected.

This feature is particularly valuable for training new radiologists on AI-assisted diagnosis, as it provides immediate access to validated reference cases. The inclusion of both typical and edge-case samples (such as small or borderline tumors) helps demonstrate the system's sensitivity and specificity in real-world scenarios. A subtle color-coding system in the background indicates confidence levels from previous analyses, giving users additional meta-information about each sample's diagnostic history.



Fig: 5.4 Upload MRI Scan Image Page

The main clinical interface combines medical-grade functionality with patient-friendly design elements, featuring a large central upload zone that accepts both drag-and-drop interactions and traditional file browsing. The interface includes intelligent pre-processing indicators that alert users to potential upload issues like motion artifacts or low-resolution scans before analysis begins. For teaching hospitals and research institutions, the system offers optional advanced controls including manual ROI (Region of Interest) adjustment and scan metadata review.

The 200MB file size limit accommodates high-resolution DICOM images while preventing server overload, with real-time compression algorithms maintaining diagnostic quality. A collapsible sidebar provides access to historical case comparisons and relevant clinical guidelines, transforming the simple upload panel into a comprehensive decision-support workstation. The "Analyze" button features a dynamic status indicator that shows preprocessing progress, giving users clear feedback during the workflow.



Fig: 5.5 Prediction and Model Metrics Page

The results interface presents a multi-layered diagnostic report designed for both efficiency and thoroughness. The primary display shows the automatically cropped brain image with optional overlay visualizations of detected anomalies, while the prediction panel uses color-coded confidence indicators (green for high-confidence negatives, amber for borderline cases, red for positive detections). Below the core metrics, the dashboard includes temporal comparison tools for patients with prior scans, displaying change-detection heatmaps when applicable.

The technical metrics section now incorporates confidence intervals and quality flags that alert clinicians to potential false positives/negatives based on image quality factors. For educational purposes, a "Model Insight" toggle reveals the CNN's activation maps showing which image features most influenced the diagnosis. The interface concludes with integrated reporting tools that auto-generate clinical notes and can interface directly with hospital EHR systems, significantly reducing documentation time while maintaining audit trails for regulatory compliance.

6. FUTURE SCOPE

The TumourTrace system has significant potential for advancement through emerging AI technologies. Future development could incorporate more sophisticated deep learning architectures, such as transformer-based models or hybrid CNN-transformer networks, to further improve detection accuracy, particularly for challenging cases. These enhanced algorithms could enable more precise differentiation between tumor types (gliomas, meningiomas, pituitary tumors) while maintaining the system's current high performance metrics. Additionally, integrating explainable AI techniques would increase clinical trust by making the model's decision-making process more transparent to medical professionals.

A critical area for innovation involves real-time monitoring capabilities during MRI procedures. Developing systems that can analyze tumor growth and changes instantaneously would revolutionize treatment planning and intervention strategies. This could be combined with advanced automated segmentation tools that precisely identify tumor boundaries without manual input, significantly reducing diagnostic time while improving measurement accuracy. Such developments would be particularly valuable for tracking treatment efficacy and monitoring post-operative recovery.

The system's early detection capabilities could be enhanced through integration with cutting-edge MRI technologies and AI algorithms sensitive to subtle pathological changes. Future versions might identify microscopic tumor formations or pre-cancerous conditions long before they become visible in conventional analysis. Parallel improvements in MRI hardware, including faster scanning protocols and more comfortable patient experiences, would complement these software advancements, making frequent monitoring more feasible.

Finally, expanding the system's diagnostic scope to incorporate multi-modal imaging analysis (combining MRI with CT, PET, or fMRI data) could provide more comprehensive tumor assessments. Cloud-based deployment would facilitate global accessibility, allowing even resource-limited clinics to benefit from advanced diagnostics. These combined hardware, software, and accessibility improvements position TumourTrace to become an increasingly vital tool in the ongoing fight against brain tumors.

7. CONCLUSION

The TumourTrace system represents a significant advancement in the field of medical diagnostics, particularly in the automated detection and classification of brain tumours using MRI scans. By leveraging the power of Convolutional Neural Networks (CNNs), the system addresses critical challenges associated with traditional diagnostic methods, such as time-consuming manual analysis, human error, and variability in tumour characteristics.

One of the key achievements of TumourTrace is its ability to automate the tumour detection process, significantly reducing the reliance on manual interpretation. Traditional MRI analysis requires radiologists to meticulously examine each scan, a process that is not only labor-intensive but also prone to subjectivity and fatigue-related errors. TumourTrace mitigates these issues by providing an objective, AI-driven analysis that can process large volumes of MRI scans in real time. This automation not only enhances diagnostic efficiency but also ensures that even small or early-stage tumours, which are often overlooked in manual reviews, are detected with high accuracy.

Beyond its immediate clinical applications, TumourTrace has the potential to transform medical research and education. The system's ability to analyze large datasets of MRI scans consistently and objectively can facilitate new insights into tumour growth patterns, treatment efficacy, and early detection strategies. Additionally, its integration into medical training programs can help students and trainees develop their diagnostic skills by providing a practical, AI-powered tool for learning and practice.

REFERENCES

[1] Chennai, India Janardhan , L.Sujihelen Chennai, India Student, Assistant Professor Department of CSE, Sathyabama Institute of Science & Technology, Chennai, India

[2] Aryan Sagar Methil, Narsee Monjee Institute of Management Studies Mumbai, India

[3] P.Mohamed Shakeel, Tarek E. El. Tobely, Haytham Al-Feel, Gunasekaran Manogaran, S.Baskar

Faculty of Information and Communication Technology, University Teknikal Malaysia Melaka, Malaysia

[4] Computer Engineering and Automatic Control Department, Faculty of Engineering, Tanta University, Tanta, Egypt

[5] Tonmoy Hossain1, Fairuz Shadmani Shishir2 , Mohsena Ashraf MD Abdullah Al Nasim, Faisal Muhammad Shah5 Dept of CSE, Ahsanullah University of Science and Technology, Dhaka, Bangladesh